SCHEMBL14770499

SCHEMBL14770499

COc1ccc(C(Oc2ccccc2)c2nc3cc(F)ccc3[nH]2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MLKL Q8NB16 4/20 0.44
▸ ALDH1A1 P00352 5/20 0.40
▸ KDM4E B2RXH2 5/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ HPGD P15428 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ AMY1A P0DUB6 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ HSD17B10 Q99714 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ACP1 P24666 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ ALPL P05186 1/20 0.36
▸ ALPI P09923 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770493 0.88 MLKL (0.38) MLKLALDH1A1KDM4EHPGDMEN1
SCHEMBL12065645 0.87 SCN10A (0.38) MLKLACP1ALPLALPIALPG
SCHEMBL14770496 0.85 MLKL (0.41) MLKLALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL12066053 0.84 MLKL (0.41) MLKLALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14770498 0.81 MLKL (0.39) MLKLALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14770727 0.81 MLKL (0.39) MLKLALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14770729 0.81 MLKL (0.39) MLKLALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14770492 0.81 AMY1A (0.41) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL14770500 0.80 MLKL (0.38) MLKLALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL14770728 0.80 ALPL (0.40) MLKLALDH1A1KDM4EHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 — — US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MLKL 2378/4885ALDH1A1 4252/4885KDM4E 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback